Zobrazeno 1 - 10
of 64
pro vyhledávání: '"C J, van Groeningen"'
Publikováno v:
Nucleosides, Nucleotides and Nucleic Acids, 35(10-12), 595-603. Taylor and Francis Ltd.
Peters, G J, Smid, K, Meijer, E, Van Groeningen, C J & Leon, L G 2016, ' Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil ', Nucleosides, Nucleotides and Nucleic Acids, vol. 35, no. 10-12, pp. 595-603 . https://doi.org/10.1080/15257770.2016.1218020
Peters, G J, Smid, K, Meijer, E, Van Groeningen, C J & Leon, L G 2016, ' Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil ', Nucleosides, Nucleotides and Nucleic Acids, vol. 35, no. 10-12, pp. 595-603 . https://doi.org/10.1080/15257770.2016.1218020
5-Fluorouracil (5FU) is still a major drug in combinations regimens for the treatment of colorectal cancer (CRC) both in the adjuvant and palliative setting. 5FU or its oral prodrug capecitabine is usually combined with irinotecan/oxaliplatin and the
Autor:
C. J. van Groeningen, Elisa Giovannetti, G.J. Peters, R. Ruijter, Henk M.W. Verheul, Giuseppe Giaccone, A. A. van Zweeden, Richard J. Honeywell, Carolien H. Smorenburg, Hans J. van der Vliet
Publikováno v:
van Zweeden, A A, van Groeningen, C J, Honeywell, R J, Giovannetti, E, Ruijter, R, Smorenburg, C H, Giaccone, G, Verheul, H M W, Peters, G J & van der Vliet, H J 2018, ' Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer ', Cancer Chemotherapy and Pharmacology, vol. 82, no. 1, pp. 39-48 . https://doi.org/10.1007/s00280-018-3588-6
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 82(1), 39-48. Springer Verlag
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 82(1), 39-48. Springer Verlag
PURPOSE: Preclinical research and prior clinical observations demonstrated reduced toxicity and suggested enhanced efficacy of cisplatin due to folic acid and vitamin B12 suppletion. In this randomized phase 2 trial, we evaluated the addition of foli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2502b3d61670f51491c3457468559503
https://research.vumc.nl/en/publications/2bf1b93c-372d-48e0-ac96-fc8c6c2699d3
https://research.vumc.nl/en/publications/2bf1b93c-372d-48e0-ac96-fc8c6c2699d3
Publikováno v:
Tijdschrift voor Urologie. 1:170-177
De angiogeneseremmer bevacizumab is, in combinatie met interferon- alfa-2a (IFNα), geregistreerd als eerstelijnsbehandeling van gevorderd en gemetastaseerd niercelcarcinoom. In dit artikel gaan we in op de toepassing van deze behandeloptie in de con
Autor:
A.C. Laan, C. J. van Groeningen, R. Ruyter, J. M. G. H. Van Riel, Richard J. Honeywell, Lemonitsa H. Mammatas, F.G. van den Berg, G.J. Peters, G. Giaccone
Publikováno v:
European Journal of Cancer, 45(14), 2519-2527. Pergamon
van Riel, J M G H, Peters, G J, Mammatas, L H, Honeywell, R J, Laan, A C, Ruijter, R, van den Berg, F G, Giaccone, G & van Groeningen, C J 2009, ' A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion ', European Journal of Cancer, vol. 45, no. 14, pp. 2519-2527 . https://doi.org/10.1016/j.ejca.2009.05.025
van Riel, J M G H, Peters, G J, Mammatas, L H, Honeywell, R J, Laan, A C, Ruijter, R, van den Berg, F G, Giaccone, G & van Groeningen, C J 2009, ' A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion ', European Journal of Cancer, vol. 45, no. 14, pp. 2519-2527 . https://doi.org/10.1016/j.ejca.2009.05.025
This study was performed to assess the toxicities, the maximum-tolerated dose (MTD), the pharmacokinetics and the anti-tumour activity of gemcitabine given by 24-h hepatic arterial infusion (HAI).Patients with liver malignancies received gemcitabine
Autor:
Inge Bramsen, C. J. van Groeningen, M.H.M. van der Linden, H.J. Kaufman, E.M. Bijvank, F.J.M. Eskens, N.K. Aaronson
Publikováno v:
Patient Education and Counseling, 70(1), 61-68. Elsevier Ireland Ltd
Bramsen, I, van der Linden, M H M, Eskens, F J M, Bijvank, E M, van Groeningen, C J, Kaufman, H J & Aaronson, N K 2008, ' Evaluation of a face-to-face psychosocial screening intervention for cancer patients: Acceptance and effects on quality of life ', Patient Education and Counseling, vol. 70, no. 1, pp. 61-68 . https://doi.org/10.1016/j.pec.2007.09.010
Bramsen, I, van der Linden, M H M, Eskens, F J M, Bijvank, E M, van Groeningen, C J, Kaufman, H J & Aaronson, N K 2008, ' Evaluation of a face-to-face psychosocial screening intervention for cancer patients: Acceptance and effects on quality of life ', Patient Education and Counseling, vol. 70, no. 1, pp. 61-68 . https://doi.org/10.1016/j.pec.2007.09.010
Objective This study evaluated a psychosocial screening intervention that offers cancer patients counselling. The assumption underlying the intervention was that barriers are often present that hamper patients’ awareness of and active request for p
Autor:
G. Giaccone, G.J. Peters, C. H. Smorenburg, W. W. Dercksen, P. Noordhuis, A. M. G. H. van Riel, Herbert M. Pinedo, Kees Smid, C. J. van Groeningen
Publikováno v:
Annals of Oncology. 17:35-42
Background: Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are essential enzymes for 5-fluorouracil (5-FU) metabolism. In patients with advanced colorectal cancer (ACRC), retrospective studies have shown that low expression level
Autor:
Epie Boven, I Zegers, C. J. van Groeningen, M Westerman, W.J.F. van der Vijgh, Miranda Verschraagen, G. Giaccone, R. Ruijter
Publikováno v:
British Journal of Cancer
BNP7787 (disodium 2,2'-dithio-bis-ethane sulphonate; Tavocept) is a novel agent developed to protect against cisplatin (cis-diammine-dichloroplatinum(II))-associated chronic toxicities. In this study, we determined the recommended dose of BNP7787 whe
Autor:
S. L. Turner, M. Swart, Jantien Wanders, G.J. Peters, Kees Smid, C. J. van Groeningen, A. H. van Gennip, Helen Gall, P. Noordhuis, A. B. P. Van Kuilenburg, Pierre Fumoleau, Jan H. Schornagel, G. Giaccone, U. Holwerda, D. Voorn
Publikováno v:
Cancer chemotherapy and pharmacology, 52(1), 1-12. Springer Verlag
S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inh
Publikováno v:
The Netherlands journal of medicine. 70(8)
Publikováno v:
The Netherlands journal of medicine. 65(4)
Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET) are rare tumours and closely related. They occur most often in children and adolescents. Few studies have been published on treatment outcome in adult patients.We performed a ret